Cysteine hydrochloride (DrugBank: Cysteine)
11 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
19 | Lysosomal storage disease | 0 |
34 | Neurofibromatosis | 0 |
84 | Sarcoidosis | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
88 | Chronic thromboembolic pulmonary hypertension | 0 |
90 | Retinitis pigmentosa | 0 |
254 | Porphyria | 2 |
296 | Biliary atresia | 0 |
310 | Congenital anomalies syndrome | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00004831 (ClinicalTrials.gov) | October 1996 | 24/2/2000 | Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria | Erythropoietic Protoporphyria | Drug: cysteine hydrochloride | FDA Office of Orphan Products Development | St. Luke's-Roosevelt Hospital Center | Completed | 18 Years | 65 Years | Both | 20 | N/A | NULL | |
2 | NCT00004940 (ClinicalTrials.gov) | May 1996 | 24/2/2000 | Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria | Erythropoietic Protoporphyria | Drug: cysteine hydrochloride | Brigham and Women's Hospital | NULL | Completed | 18 Years | 65 Years | Both | 50 | Phase 3 | NULL |